Author: Rahbar Saadat, Yalda; Hosseiniyan Khatibi, Seyed Mahdi; Zununi Vahed, Sepideh; Ardalan, Mohammadreza
Title: Host Serine Proteases: A Potential Targeted Therapy for COVID-19 and Influenza Cord-id: ki0f068q Document date: 2021_8_30
ID: ki0f068q
Snippet: The ongoing pandemic illustrates limited therapeutic options for controlling SARS-CoV-2 infections, calling a need for additional therapeutic targets. The viral spike S glycoprotein binds to the human receptor angiotensin-converting enzyme 2 (ACE2) and then is activated by the host proteases. Based on the accessibility of the cellular proteases needed for SARS-S activation, SARS-CoV-2 entrance and activation can be mediated by endosomal (such as cathepsin L) and non-endosomal pathways. Evidence
Document: The ongoing pandemic illustrates limited therapeutic options for controlling SARS-CoV-2 infections, calling a need for additional therapeutic targets. The viral spike S glycoprotein binds to the human receptor angiotensin-converting enzyme 2 (ACE2) and then is activated by the host proteases. Based on the accessibility of the cellular proteases needed for SARS-S activation, SARS-CoV-2 entrance and activation can be mediated by endosomal (such as cathepsin L) and non-endosomal pathways. Evidence indicates that in the non-endosomal pathway, the viral S protein is cleaved by the furin enzyme in infected host cells. To help the virus enter efficiently, the S protein is further activated by the serine protease 2 (TMPRSS2), provided that the S has been cleaved by furin previously. In this review, important roles for host proteases within host cells will be outlined in SARS-CoV-2 infection and antiviral therapeutic strategies will be highlighted. Although there are at least five highly effective vaccines at this time, the appearance of the new viral mutations demands the development of therapeutic agents. Targeted inhibition of host proteases can be used as a therapeutic approach for viral infection.
Search related documents:
Co phrase search for related documents- active site and acute lung injury: 1, 2
- active site and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute aki kidney injury and adaptive immunity: 1
- acute aki kidney injury and adaptive immunity innate: 1
- acute aki kidney injury and additional evidence: 1
- acute aki kidney injury and adhesion molecule: 1
- acute ards respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and adaptive immunity innate: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and additional evidence: 1, 2, 3
- acute ards respiratory distress syndrome and adhesion molecule: 1, 2, 3, 4, 5, 6
- acute lung injury and adaptive immunity: 1, 2, 3, 4, 5, 6
- acute lung injury and adaptive immunity innate: 1, 2, 3, 4
- acute lung injury and additional evidence: 1
- acute lung injury and adhesion molecule: 1, 2, 3, 4, 5, 6, 7, 8
- acute myocardial damage and additional evidence: 1
- acute myocardial damage and adhesion molecule: 1
- acute respiratory syndrome coronavirus and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome coronavirus and adaptive immunity innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome coronavirus and additional evidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
Co phrase search for related documents, hyperlinks ordered by date